In this study, we examined the role of protein kinase C (PKC)-E in the apoptosis and survival of glioma cells using tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-stimulated cells and silencing of PKCE expression. Treatment of glioma cells with TRAIL induced activation, caspasedependent cleavage, and down-regulation of PKCE within 3 to 5 hours of treatment. Overexpression of PKCE inhibited the apoptosis induced by TRAIL, acting downstream of caspase 8 and upstream of Bid cleavage and cytochrome c release from the mitochondria. A caspase-resistant PKCE mutant (D383A) was more protective than PKCE, suggesting that both the cleavage of PKCE and its down-regulation contributed to the apoptotic effect of TRAIL. To further study the role of PKCE in glioma cell apoptosis, we employed short interfering RNAs directed against the mRNA of PKCE and found that silencing of PKCE expression induced apoptosis of various glioma cell lines and primary glioma cultures. To delineate the molecular mechanisms involved in the apoptosis induced by silencing of PKCE, we examined the expression and phosphorylation of various apoptosis-related proteins. We found that knockdown of PKCE did not affect the expression of Bcl2 and Bax or the phosphorylation and expression of Erk1/2, c-Jun-NH 2 -kinase, p38, or STAT, whereas it selectively reduced the expression of AKT. Similarly, TRAIL reduced the expression of AKT in glioma cells and this decrease was abolished in cells overexpressing PKCE. Our results suggest that the cleavage of PKCE and its down-regulation play important roles in the apoptotic effect of TRAIL. Moreover, PKCE regulates AKT expression and is essential for the survival of glioma cells. (Cancer Res 2005; 65(16): 7301-9) 
Introduction
Protein kinase C (PKC), a family of phospholipid-dependent serine-threonine kinases plays important roles in various cellular functions (1) . PKC consists of at least 10 isoforms that are divided into the classic PKCs (a, h1, h2, and g), the novel PKCs (y, q, D, and u), and the atypical PKCs (PKC~and PKCL/E; ref. 2) . Various PKC isoforms have been reported to regulate cell apoptosis in a stimulus-and isoform-dependent manner. Thus, PKCa and PKCL have been mainly associated with antiapoptotic effects in various systems (3, 4) , whereas PKCy, u, and A have been implicated as proapoptotic kinases (5, 6) . The novel and atypical PKC isoforms have been reported to undergo caspase-dependent cleavage in response to various apoptotic stimuli and the accumulation of their constitutively active catalytic fragments has been associated with the regulation of cell apoptosis (7, 8) .
PKCq has been implicated in the regulation of both cell survival and apoptosis in various cellular systems. Thus, overexpression of PKCq protected MCF-7 cells from tumor necrosis factor (TNF)-ainduced apoptosis (9) and promoted the survival of lung cancer cells (10) . In contrast, PKCq has been shown to mediate neuronal death induced by oxidative stress (11) and the apoptosis of macrophages in response to lipopolysaccharide via c-Jun NH 2 -terminal kinase (JNK) activation (12) . PKCq is overexpressed in gliomas (13, 14) ; however, its role in the regulation of glioma cell apoptosis has not been extensively studied.
TNF-related apoptosis inducing ligand (TRAIL; Apo2 ligand) belongs to the TNF superfamily (15) . TRAIL induces apoptosis in transformed cells via binding to the death receptors TRAIL-R1 and TRAIL-R2 (16, 17) . The mechanisms underlying TRAIL-induced apoptosis consist of the formation of the death-inducing signaling complex that is also common to other members of the death receptors (18) . This leads to activation of caspase 8 at the deathinducing signaling complex followed by either activation of a mitochondrial-independent pathway via caspase 3 and 7 or activation of a mitochondrial-dependent pathway by activation of caspase 9 (19) . In addition, recent studies reported that TRAIL activates the transcriptional nuclear factor nB (NF-nB) and JNK in various cellular systems (20) and that NF-nB (21) and phosphoinositide-3-kinase/AKT (22) are involved in the resistance of some transformed cells to the apoptotic effect of TRAIL. PKC signaling has also been shown to modulate TRAIL-induced apoptosis by inhibiting the recruitment of key DD-containing adaptor proteins to their membrane associated signaling complexes (23, 24) .
Here, we studied the role of PKCq in the apoptosis and survival of glioma cells using the apoptotic stimulus TRAIL and silencing of PKCq. We found that TRAIL induced caspase-dependent cleavage and down-regulation of PKCq and that both the loss of full-length PKCq and its cleavage play important roles in the apoptotic function of TRAIL. Moreover, our results using short interfering RNAs (siRNA) further indicate that the expression of PKCq is essential for the survival of glioma cells and implicate AKT in this response. The caspase  inhibitors, Z-DEVD-FMK, Z-VAD-FMK, Z-IETD-FMK, Z-LEHD-FMK and  the PKCq peptide (ERMRPRKRQGSVRRRV) were obtained from Calbiochem (La Jolla, CA) .
Glioma cells and cell transfection. The glioma cell lines, A172, U87, U251 and LN-229, were grown on tissue culture dishes in medium consisting of DMEM containing 10% FCS, 2 mmol/L glutamine, penicillin (50 units/mL), and streptomycin (0.05 mg/mL).
Primary cultures were obtained from freshly resected tissues following 1 hour of surgical removal. Institutional Review Board-approved informed consent was obtained from all patients or from the patient's guardian for use of tumor tissue collected at the time of tumor resection. Samples were first washed in PBS and then minced into small pieces in DMEM with 10% FCS and were further triturated to obtain maximal cell dispersion. Cells were plated in 25 cm 2 tissue culture flasks and were grown for 7 to 10 days. Cultures were used up to passage 7.
Cells were transfected either with the control vectors or with the different PKCq expression vectors by electroporation using the Nucleofector device (Amaxa Biosystems, Germany). Transfection efficiency using nucleofection was about 80% to 90%.
Site-directed mutagenesis of PKCE. PKCq cloned into the pCMVtag2B plasmid served as a template vector for the site-directed mutagenesis. The caspase cleavage site of PKCq (D383A) was mutated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and the following primers: sense, (5V ) GTCGGCCACCGCTGGCCAGCTGG (3V ); antisense, (5V ) CCAGCTGGCCAGCGGTGGCCGAC (3V ). The mutation was confirmed by DNA sequencing.
Construction of PKCE green fluorescent protein fusion protein. cDNA encoding PKCq was fused into the NH 2 -terminal-enhanced green fluorescent protein (GFP) vector pEGFP-N1 (Clontech, Palo Alto, CA). The original pEGFP-N1 vector was modified by the insertion of a MluI site in the plasmid polylinker as previously described (25) . The clone containing the GFP-PKCq was constructed by the excision of PKCq from MTH-PKC plasmids by digestion with XhoI and MluI. The insert was then ligated into the modified GFP vector using the same restriction sites. DNA sequencing of the GFP-PKC constructs confirmed the intended reading frame.
Adenovirus preparation and infection. The AdEasy system was kindly provided by Dr. Vogelstein (The Johns Hopkins University School of Medicine, MD; ref. 26) . PKCq and PKCq kinase-dead mutants were first cloned into the pShuttle-CMV vector as previously described for PKCy (27) . Cells were incubated with a multiplicity of infection of 5 at the appropriate recombinant adenovirus vectors for 1 hour. The medium was then replaced with fresh medium and the cells were used 24 to 48 hours post-infection.
Short interfering RNA transfection. siRNA duplexes were synthesized and purified by Dharmacon (Lafayette, CO). The siRNA sequence for targeting PKCq mRNA was 5V-GAUGAAGGAGGCGCUCAGTT-3V. A scrambled sequence was used as a negative control. In addition, we used a pool of four PKCq siRNA duplexes which were also obtained from Dharmacon. Transfection of siRNAs was done using 50 nmol/L PKCq or scrambled siRNAs and OligofectAMINE (Invitrogen, Carlsbad, CA) according to the Figure 1 . TRAIL induces activation, cleavage, and down-regulation of PKCq in glioma cells. A172 cells were treated with TRAIL for 0 to 3 hours and the activity of PKCq was determined using an immune complex PKCq kinase assay. Samples were also subjected to immunoblot analysis for the determination of total PKCq levels (A ). Translocation of PKCq in response to TRAIL was determined in A172 cells transfected with PKCq-GFP. Cells were stimulated with TRAIL (100 ng/mL) for various periods of time and were then visualized by confocal microscopy (B). Cleavage and expression of PKCq was determined in A172 cells treated with TRAIL for 0 to 5 hours by Western blot using an anti-PKCq antibody that recognizes the catalytic domain [anti-PKCq (C-15), Santa Cruz] and cell apoptosis was measured in parallel using PARP cleavage (C ). The role of caspase 3, 8, and 9 in the cleavage of PKCq was determined using pretreatment of the cells with DEVD, ZVAD, Z-IRTD, or Z-LEHD (10 Amol/L) for 30 minutes followed by incubation with TRAIL for an additional 3 hours (D ). Columns, means; bars, F SE (A ); results from one of four separate experiments which gave similar results (B , C , and D ).
manufacturer's instructions. PKCq protein levels were determined using Western blot analysis.
Measurements of cell apoptosis. Cell apoptosis was measured using propidium iodide staining and analysis by flow cytometry as previously described (25) . Briefly, detached cells and trypsinized adherent cells were pooled, fixed in 70% ethanol for 1 hour on ice, washed with PBS and treated for 15 minutes with RNase (50 Amol/L) at room temperature. Cells were then stained with propidium iodide (5 Ag/mL) and analyzed on a Becton Dickinson (Mountain View, CA) cell sorter. Cell apoptosis was also examined by Western blot analysis of PARP cleavage using anti-PARP antibody (BD PharMingen, San Diego, CA) and by trypan blue exclusion assay.
Preparation of cell homogenates and immunoblot analysis. Cell pellets were resuspended in 100 AL of lysis buffer [25 mmol/L Tris-HCl (pH 7.4), 50 mmol/L NaCl, 0.5% Na deoxycholate, 2% NP40, 0.2% SDS, 1 mmol/L PMSF, 50 Ag/mL aprotinin, 50 Amol/L leupeptin, 0.5 mmol/L Na 3 VO 4 ] on ice for 15 minutes. Sample buffer (2Â) was added and the samples were boiled for 5 minutes. Lysates were resolved by SDS-PAGE and were transferred to nitrocellulose membranes. Following incubation with the primary antibody, specific reactive bands were detected using a goat anti-rabbit or goat antimouse IgG conjugated to horseradish peroxidase (Bio-Rad, Hercules, CA) and by enhanced chemiluminescence Western blotting detection kit (Amersham, Arlington Heights, IL). Equal loading was verified by Ponceau S staining or by using anti-actin or anti-tubulin antibodies.
Cytochrome c release. Cytochrome c release from the mitochondria was determined in the cytosolic fraction. Mitochondrial and cytosolic fractions were isolated using the ApoAlert Cell Fractionation Kit (Clontech, BD Biosciences) according to the manufacturer's instructions. Cytochrome c was identified in the cytosolic fraction using a rabbit anti-cytochrome c antibody.
Measurement of caspase 8 activity. Caspase 8 activity was measured using the QuantiPak assay kit obtained from Biomol (Plymouth Meeting, PA) using the fluorescent substrate Ac-IETD-AMC according to the manufacturer's recommendations.
Immunoprecipitation and immune complex PKCe kinase assay. Immunoprecipitation of PKCq and the PKCq kinase assay were done as previously described (28) . Briefly, cells treated with TRAIL were lysed in lysis buffer [10 mmol/L Tris-HCl (pH 7.5), 2 mmol/L EDTA and EGTA, 0.5 mmol/L DTT, 200 Amol/L PMSF, 1 Ag/mL aprotinin, 2 Ag/mL leupeptin, 100 Amol/L sodium orthovanadate, and 0.2% Triton X-100]. Lysates were centrifuged at 4jC and supernatants were incubated with 4 Ag of anti-PKCq antibody for 1 hour at 4jC followed by incubation with 100 AL of protein A/G PLUSAgarose beads for an additional 4 hours. Immunoprecipitates were then used in a kinase assay that was carried out in 200 AL of reaction mixture containing 20 mmol/L HEPES (pH 7.4), 10 mmol/L MgCl 2 , 0.1 mmol/L EGTA, 0.1 mg/mL PKCq-specific substrate (ERMRPRKRQGSVRRRV), 200 Ag/mL phosphatidylserine, 20 Ag/mL diacylglycerol, 0.1 mmol/L ATP, and 0.1 ACi/reaction of g-P 32 -ATP. The reaction mixture was preincubated for 3 minutes in 30jC. Reactions were initiated by adding 25 AL of preincubated mixture to the immunoprecipitates and incubation at 30jC for 10 minutes. Reaction was terminated by spotting 10 AL of each supernatant onto the phosphocellulose filter papers (P-81). The filters were washed thrice in 0.5% phosphoric acid and counted for radioactivity. Cell pellets were separated by PAGE and immunoblotted for PKCq to normalize for the small differences in the amount of immunoprecipitated kinase.
Statistical analysis. The results are presented as the mean F SE. Data were analyzed using ANOVA and a paired Student's t test to determine the level of significance between the different groups.
Results
TRAIL induces caspase-dependent cleavage and downregulation of PKCE in glioma cells. PKCe has been implicated in the regulation of cell apoptosis in various cellular systems (9) (10) (11) (12) . To examine the role of PKCe in glioma cell apoptosis, we first employed the apoptotic stimulus TRAIL and the A172 glioma cells which are highly sensitive to this ligand. TRAIL induced activation of PKCe, initial activation was observed after 15 minutes of treatment, and was further increased after 2 to 3 hours of treatment (Fig. 1A) . The activation of PKCq was followed by translocation of PKCq to the plasma membrane within 15 minutes of treatment as was observed using PKCq tagged to GFP (Fig. 1B) . In addition, TRAIL induced cleavage of PKCq and a gradual loss of the full-length isoforms (Fig. 1C) . Low levels of the catalytic fragment of PKCq (43 kDa) were already observed after 1 hour, whereas higher levels of this fragment were observed after 2 to 3 hours of treatment. At this time, the expression of the full-length PKCq was significantly reduced, and by 5 hours, PKCq expression was barely detected (Fig. 1C) . The accumulation of the catalytic fragment of PKCq preceded the cleavage of PARP, which was first detected after 3 hours of TRAIL treatment (Fig. 1C) and the onset of cell apoptosis as measured using propidium iodide staining and fluorescence-activated cell sorting analysis (data not shown).
Pretreatment of the cells with the caspase inhibitors Z-VAD (pan-caspase), DEVD (caspases 3), and Z-IETD (caspase 8) for 30 minutes prior to TRAIL administration inhibited the cleavage of PKCq by TRAIL, whereas the caspase 9 inhibitor, Z-LEHD elicited a partial inhibitory effect (Fig. 1D) . Similarly, the caspase inhibitors significantly reduced the apoptosis induced by TRAIL as evidenced by PARP cleavage (data not shown).
Cleavage and down-regulation of PKCE in TRAIL-sensitive and resistant glioma cells. The cleavage and down-regulation of PKCq were further studied in various TRAIL-sensitive and resistant glioma cell lines and in primary glioma cultures (Fig. 2) . TRAIL induced a decrease in the expression of the full-length PKCq and accumulation of the PKCq catalytic fragment in the TRAILsensitive cell lines (A172, U251, and U87) albeit to a different degree (Fig. 2B) . Thus, the full-length PKCq was significantly decreased and high levels of the 43 kDa fragment accumulated in the A172 and U251 cells that exhibited high sensitivity to the apoptotic effect of TRAIL, whereas smaller changes were observed in the U87 cells that exhibited lower sensitivity to TRAIL ( Fig. 2A  and B) . In contrast, no cleavage of PKCq was observed in the TRAIL-resistant cell line, LN-229 ( Fig. 2A and B) , even when the cells were examined after 24 hours of TRAIL treatment (data not shown), suggesting a role of the cleaved form of PKCq in the apoptotic effect of TRAIL.
Similar results were observed with the primary glioma cells. An increase in the catalytic fragment and a decrease in the full-length PKCq were observed in the TRAIL-sensitive glioma cultures (HF 1308 and HF 1255), whereas no changes were observed in the TRAIL-resistant primary glioma cells (HF 1286 and HF1318) following 5 hours (Fig. 2C and D) or 24 hours of treatment (data not shown).
Overexpression of PKCE protects glioma cells from the apoptosis induced by TRAIL. Because the expression of PKCq was dramatically decreased in TRAIL-treated cells, we examined whether overexpression of PKCq can protect the A172 cells from apoptosis induced by TRAIL. For these experiments, we used both an adenovirus vector expressing PKCq and the tg2b-PKCq expression vector. As presented in Fig. 3A , both infection of the A172 cells with an adenovirus vector expressing PKCq and transfection of the cells resulted in overexpression of PKCq and treatment of the cells with TRAIL induced cleavage of the PKCq (Fig. 3A) . Overexpression of PKCq decreased the apoptosis of the A172 cells in response to TRAIL as compared with control LacZAd-infected cells or as compared with the control vectortransfected cells (Fig. 3B) . Thus, PKCq decreased cell apoptosis by about 50% as compared with control vector cells.
Overexpression of PKCq did not inhibit the activation of caspase 8 by TRAIL (data not shown); however, it abolished the decrease in Bid expression (Fig. 3C ) and the release of cytochrome c from the mitochondria to the cytosol (Fig. 3D) , suggesting that PKCq acted downstream of caspase 8 activation and upstream of Bid cleavage and activation of the mitochondria pathway.
The PKCE caspase-resistant mutant (D383A) is more protective than PKCE against TRAIL-induced apoptosis. The partial protection of the exogenous PKCq against the apoptosis induced by TRAIL could be due to an apoptotic function of the cleaved overexpressed PKCq. To examine this possibility, we constructed a PKCq mutant in which the aspartic acid at the SSPD site was mutated to alanine (D383A mutant). Following transfection, the A172 cells expressed comparable levels of PKCq and the PKCq D383A mutant (Fig. 4A) . Similar to the results described in Fig. 3 , the wild-type PKCq underwent cleavage in response to TRAIL (Fig. 4A) and decreased the apoptosis of the cells by about 40% to 50% cells, as shown by measurements of cell apoptosis (Fig. 4B) and by the morphologic appearance of the cells (Fig. 4C) . In contrast, the PKCq D383A did not undergo cleavage in response to TRAIL treatment (Fig. 4A) and overexpression of this mutant exerted a stronger protective effect against the apoptosis induced by TRAIL. Thus, in these cells, only 5% to 10% of the cells were apoptotic as compared with 55% to 60% apoptotic cells in the control vector cells (Fig. 4B and C) . These results suggest that the PKCq D383A acted as a dominant-negative of PKCq and that the cleavage of PKCq contributed to the apoptosis induced by TRAIL. Similarly, we found that the expression of active caspase 3 induced by TRAIL was inhibited by PKCq and to a larger degree by the PKCq D338A mutant (Fig. 4D) .
Silencing of PKCE induces apoptosis of glioma cells. Our results thus far suggest that the loss of PKCq contributes to the apoptosis induced by TRAIL. We therefore examined whether the expression of PKCq was essential for the survival of glioma cells. For these experiments, we designed a siRNA targeting the human PKCq mRNA (q1 siRNA). In addition, we employed a pool of four PKCq siRNA duplexes (Dharmacon, q2 siRNA). Transfection of the A172 cells with either PKCq siRNAs decreased the expression of PKCq in the cells by 90% after 3 days of transfection (Fig. 5A) , whereas it did not affect the levels of the other PKC isoforms Figure 4 . Cleavage of PKCq plays a role in the apoptotic effect of TRAIL. A172 cells were transfected with control vector, PKCq, or PKCqD383A. Following 48 hours, the cells were treated with TRAIL for 5 hours and the cleavage of PKCq was determined using Western blot analysis (A ). Cell apoptosis was determined using propidium iodide staining and fluorescence-activated cell sorting analysis (B ). The cells were also visualized using a phase contrast microscope (C ). The levels of active caspase 3 were determined using Western blot analysis (D ). The results are representative of four similar experiments (A, C , and D); columns, means; bars, F SE (B ). expressed in the A172 cells (PKCa, h, g, y,~and A; data not shown). The PKCq siRNA transfected cells exhibited a high degree of cell apoptosis as compared with cells transfected with control scrambled siRNA as determined by propidium iodide staining and fluorescence-activated cell sorting analysis (Fig. 5A) or by histone ELISA (data not shown).
Similar results were obtained with the LN-443, U251, and U87 glioma cell lines (Fig. 5B) and with the two primary glioma cell cultures, HF1308 and HF 1255 (Fig. 5C and D) . Transfection of these cells with the PKCq siRNAs significantly reduced the expression of PKCq in these cells (Fig. 5B and C) and increased cell death of the transfected cells as shown by propidium iodide staining (Fig. 5B) , the morphologic appearance of the cells and by trypan blue exclusion assay (Fig. 5D) .
Loss of PKCE induces a decrease in the expression of Akt. To explore the mechanisms by which knockdown of PKCq induces cell apoptosis in glioma cells, we examined the expression and phosphorylation of various apoptosis-related proteins in the A172 cells transfected with the PKCq siRNA. As presented in Fig. 6A , knockdown of PKCq specifically decreased the expression of PKCq, whereas no changes were observed in the expression of PKCy. The silencing of PKCq increased the expression of active caspase 3, whereas it did not affect the expression of the apoptosis-related proteins, Bax and BCl 2 , or the phosphorylation and expression of the kinases JNK, Erk, p38, and STAT1 (Fig. 6A) . In contrast, the knockdown of PKCq expression significantly inhibited the phosphorylation and expression of AKT in these cells (Fig. 6A) .
Because silencing of PKCq reduced the expression of AKT, we examined whether loss of PKCq expression in response to TRAIL treatment also reduced the expression of this protein. For these experiments, we used cells transfected with control vector and PKCq and treated them with TRAIL for 3 hours. As presented in Fig. 6B , treatment of control vector cells with TRAIL significantly decreased the expression of AKT in the cells after 3 hours of treatment (a time in which PKCq was cleaved and degraded). In contrast, no significant decrease in AKT expression was observed in cells overexpressing PKCq, suggesting the down-regulation of PKCq expression induced by TRAIL mediated the decrease in AKT expression. 
Discussion
In this study, we explored the role of PKCq in the apoptosis and survival of glioma cells using the apoptotic stimulus TRAIL and siRNAs directed against PKCq mRNA. We found that TRAIL induced activation of PKCq within 15 to 30 minutes of TRAIL treatment which was further increased after 3 hours. The early and late activation of PKCq are probably mediated by two distinct mechanisms; a cleavage-independent activation at the early time points and a cleavage-dependent activation at the later time point which could be attributed to the generation of a constitutively active catalytic fragment. Indeed, similar results of cleavagedependent activation of PKCq were recently reported in TNF-a treated cells (9) .
TRAIL also induced translocation of PKCq to the plasma membrane. The translocation of PKC is associated with the activation of this enzyme and it is considered as an important molecular event in the function of this kinase family (29) . Translocation of PKC is mediated by binding to selective anchoring proteins or selective receptors for activated C-kinases (RACK; ref. 30 ) and several domains of PKCq have implicated its translocation and anchoring to the membrane (31) . The mechanisms by which TRAIL induces translocation of PKCq and the role of this translocation in PKCq effects are currently not understood. However, membranal translocation of PKCq has been associated with the apoptotic effect of UV radiation (32) .
TRAIL induced cleavage and down-regulation of PKCq and generation of a 43 kDa fragment in all the cells that were sensitive to TRAIL. In contrast, no cleavage of PKCq was observed in the TRAIL-resistant glioma cells, suggesting that the cleavage and loss of PKCq were involved in the apoptotic response of TRAIL. Various studies have shown that PKC isoforms are proteolytically cleaved in response to apoptotic stimuli and that the apoptotic effect of some of these isoforms is associated with the accumulation of the cleaved constitutive active catalytic fragment (6, 33) . Indeed, cleavage of PKCy (26, 34) , PKCu (35) , PKCA (7), and PKC~ (36) have been reported in response to various apoptotic stimuli such as radiation, chemotherapeutic drugs and ligation of the FAS and TNF-a receptors, and caspase 3 has been implicated in the cleavage of these PKC isoforms (6, 7, 26, 34) .
PKCq undergoes cleavage in response to serum deprivation (37), chemotherapeutic agents (38) and TNF-a treatment (9). Koriyama et al. (29) and Hoppe et al. (37) showed both in vitro and in vivo, that caspase 3 mediated the cleavage of PKCq in their cellular systems. In contrast, Basu et al. (9) reported that in the MCF-7 cells that lack functional caspase 3, the cleavage of PKCq is mediated by caspase 7. We found that TRAIL induced the generation of a 43 kDa fragment in all the glioma cells that were examined in this study, and no other catalytic fragments were detected. Using different caspase inhibitors, we found that the caspase 3 and caspase 8 inhibitors completely inhibited the cleavage of PKCq and the apoptosis induced by TRAIL, whereas partial inhibition was observed with the caspase 9 inhibitor. Thus, our data suggest that in glioma cells, TRAIL exerts apoptosis via activation of caspases 8 and 9 and that caspase 3 cleaves PKCq at the atypical cleavage site, SSPD in the hinge region.
We found that TRAIL induced a large decrease in the expression of the full-length PKCq in parallel to the increased generation of its cleaved catalytic fragment. PKCq has been associated with antiapoptotic functions in various cellular systems including lung cancer cells (10) , T lymphocytes (39) , and prostate cancer cells (40) . We therefore hypothesized that the down-regulation of PKCq mediated the apoptotic effect of TRAIL. We found that overexpression of PKCq in the A172 cells inhibited the apoptosis induced by TRAIL, acting downstream from caspase 8 activation and upstream of Bid cleavage and activation of the mitochondrial pathway. Overexpression of PKCq inhibited the apoptosis induced by TRAIL by 50% to 60%, suggesting that the down-regulation of PKCq may not be the only factor involved in the apoptotic effect of TRAIL. A partial protective effect of PKCq on the apoptosis of glioma cell lines treated with TRAIL was also observed by Shinohara et al. (41) . The overexpressed PKCq underwent cleavage in TRAIL-treated cells, similar to the endogenous PKCq, suggesting that the partial protective effect of PKCq may be due to an apoptotic effect of the cleaved fragment. We found that a PKCq mutant in which aspartic acid 383 was mutated to alanine (D383A) and which did not undergo cleavage in response to TRAIL, was significantly more effective than the wild-type PKCq in protecting A172 cells from apoptosis induced by TRAIL. Thus, our results suggest that the cleavage of PKCq contributed to the apoptotic effect of TRAIL in glioma cells. The cleaved PKCq has been associated with both pro-and antiapoptotic effects in various cellular systems. Thus, apoptotic effects of the cleaved PKCq catalytic fragment were observed in the GH3B6 cells (38) , whereas Basu et al. (9) reported that the catalytic domain of PKCq exerted an antiapoptotic effect in TNF-a-treated cells.
The down-regulation of PKCq in TRAIL-treated glioma cells raised the possibility that the expression of PKCq is essential for the survival of these cells. Using siRNAs directed against PKCq mRNA, we reduced PKCq expression in the cells by 90%. Silencing of PKCq expression induced cell apoptosis in all the glioma cell lines and primary cultures that were examined, further suggesting an important role of PKCq in the survival of glioma cells.
We found that the decrease in PKCq expression by either siRNAs or TRAIL induced a selective decrease in the expression of AKT, whereas the expression of other apoptosis-related proteins was not significantly affected. AKT (PKB) is a family of serine-threonine kinases that regulates cell survival in a variety of cellular systems including gliomas (42, 43) . The survival effects of AKT are exerted by phosphorylating proteins such as BAD, caspase 9, and the forkhead transcription factors or by activating antiapoptotic pathways such as NF-nB (43) . The activity of AKT is regulated by phosphorylation on Thr 308 by PDK-1 and on Ser 473 by an unidentified kinase referred to as PDK-2 (44) . In addition, the activity of AKT is also regulated by its degradation via diverse mechanisms. Indeed, proteasomedependent degradation of AKT has been reported in response to treatment of tumor cells with Hsp90-specific inhibitors (45), whereas caspase-dependent and independent degradation of AKT occurs in response to p53 inhibition of the a6h4 integrin survival signaling (46) , UV radiation (47) , and inhibition of the vascular endothelial growth factor receptor pathway (48) . The mechanisms by which loss of PKCq induced a decrease in the expression of AKT are currently not understood. One possibility is that down-regulation of PKCq induced activation of caspase 3 that results in the cleavage and degradation of AKT. Indeed, silencing of PKCq induced activation of caspase 3 and overexpression of PKCq decreased the activation of caspase 3 induced by TRAIL. Alternatively, down-regulation of the Hsp90 protein, which is required for the stability of AKT, is another possible mechanism because PKC has been associated with the regulation of Hsp90 under various conditions (49) . Finally, the direct regulation of AKT expression by PKCq may be also considered because interaction between AKT and PKCq has been shown in various cellular systems (50) .
In summary, the results of both TRAIL-induced apoptosis and PKCq silencing indicate that the expression of AKT is regulated by PKCq and that PKCq is essential for the survival of glioma cells. Our results also suggest that in TRAIL-treated cells, the cleaved PKCq contributes to the apoptotic effect of TRAIL, in addition to the loss of this isoform from the cells. Thus, in addition to delineating the role of PKCq in TRAIL-induced apoptosis, the results of this study have broader implications for the role of PKCq signaling in the regulation of AKT expression and for glioma cell function. We (13) and others (14) have recently reported that PKCq is highly expressed in glioblastomas. Thus, our results that PKCq is essential for the survival of glioma cells identify an important role of PKCq in these tumors.
